RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval

Written by Petra Hegmann on 13th September 2021. Posted in Client News.

• Previous
• Next